scholarly journals About primary gastric sarcoma

2021 ◽  
Vol 32 (5-6) ◽  
pp. 464-468
Author(s):  
D. S. Klebanov
Keyword(s):  
Satisfactory Result ◽  
Surgical Intervention ◽  
Malignant Tumors ◽  
Early Recognition ◽  
Malignant Neoplasms ◽  
Radical Method ◽  
Radical Intervention

The only radical method of treatment of malignant neoplasms of the stomach today is surgical, surgical intervention. The results of such an intervention are closely related to how timely and. it is radically produced. It is therefore clear that in relation to malignant tumors of the stomach, it is not important to recognize the disease in general, but to early recognition, in which radical intervention can give a satisfactory result.

scholarly journals Current approaches to surgical treatment of pancreatic head cancer

2021 ◽  
Vol 12 (4) ◽  
pp. 5-13
Author(s):  
Maxim Yu. Kabanov ◽  
Nikolay I. Glushkov ◽  
Konstantin V. Sementsov ◽  
Anatoliy V. Skorodumov ◽  
Valentin V. Alekseev ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Surgical Intervention ◽  
Malignant Tumors ◽  
Pancreatic Head ◽  
Malignant Neoplasms ◽  
Extensive Experience ◽  
Head Cancer ◽  
Main Method ◽  
Pancreatic Head Cancer ◽  
The Past

Pancreatic cancer accounts for 810% of all cases of malignant tumors of the digestive organs and 5060% of pancreaticoduodenal malignant neoplasms. Over the past 30 years the incidence of pancreatic cancer in Russia has increased by 30%. The main method of treatment this category of patients requires surgical intervention. Extensive experience has been gained in using various types of surgical therapy. The review analyzes the results of modern studies on the efficacy and safety of the most common of them.

The possibility of using tantalum oxide microparticles in phosphate glass for radiation therapy of malignant neoplasms

2020 ◽  
pp. 85-87
Author(s):  
O. S. Plotnikova ◽  
V. I. Apanasevich ◽  
M. A. Medkov ◽  
A. A. Polezhaev ◽  
V. I. Nevozhai ◽  
...  
Keyword(s):  
Phosphate Glass ◽  
Linear Accelerator ◽  
Malignant Tumors ◽  
Video Recording ◽  
Tantalum Oxide ◽  
Vertical Plane ◽  
Secondary Radiation ◽  
Semiconductor Diode ◽  
Malignant Neoplasms ◽  
Diode Detector

Objective: The creation of the medicine for a local radiomodification of tumors.Methods: The level of the secondary radiation on the surface of the phosphate glass powder with the inclusion of tantalum oxide processed by 6 MeV deceleration emission was studied. Medical linear accelerator TrueBeam (Varian, USA), and Semiconductor diode detector PDI 2.0 (Sun Nuclear Corp., USA) having the system of moving in vertical plane and the system of position video recording were used.Results: The presence of the phosphate glass (containing 20% Та2О5) on the surface gave a 63.7% increase to the secondary radiation. It’s around two thirds of the overall level.Conclusion: An opportunity to create a medicine on the basis of phosphate glass, containing tantalum oxide, for local radiomodification of malignant tumors. 

scholarly journals Aspartame and cancer – new evidence for causation

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Philip J. Landrigan ◽  
Kurt Straif
Keyword(s):  
Public Health ◽  
Cancer Risk ◽  
Malignant Tumors ◽  
Daily Intake ◽  
Immunohistochemical Analysis ◽  
International Agency ◽  
Advisory Group ◽  
Malignant Neoplasms ◽  
Acceptable Daily Intake ◽  
New Findings

Abstract Background Aspartame is one of the world’s most widely used artificial sweeteners and is an ingredient in more than 5000 food products globally. A particularly important use is in low-calorie beverages consumed by children and pregnant women. The Ramazzini Institute (RI) reported in 2006 and 2007 that aspartame causes dose-related increases in malignant tumors in multiple organs in rats and mice. Increased cancer risk was seen even at low exposure levels approaching the Acceptable Daily Intake (ADI). Prenatal exposures caused increased malignancies in rodent offspring at lower doses than in adults. These findings generated intense controversy focused on the accuracy of RI’s diagnoses of hematopoietic and lymphoid tissue tumors (HLTs). Critics made the claim that pulmonary lesions observed in aspartame-exposed animals were inflammatory lesions caused by Mycoplasma infection rather than malignant neoplasms. Methods To address this question, RI subjected all HLTs from aspartame-exposed animals to immunohistochemical analysis using a battery of markers and to morphological reassessment using the most recent Internationally Harmonized Nomenclature and Diagnostic (INHAND) criteria. Findings This immunohistochemical and morphological re-evaluation confirmed the original diagnoses of malignancy in 92.3% of cases. Six lesions originally diagnosed as lymphoma (8% of all HLTs) were reclassified: 3 to lymphoid hyperplasia, and 3 to chronic inflammation with fibrosis. There was no evidence of Mycoplasma infection. Interpretation These new findings confirm that aspartame is a chemical carcinogen in rodents. They confirm the very worrisome finding that prenatal exposure to aspartame increases cancer risk in rodent offspring. They validate the conclusions of the original RI studies. These findings are of great importance for public health. In light of them, we encourage all national and international public health agencies to urgently reexamine their assessments of aspartame’s health risks - especially the risks of prenatal and early postnatal exposures. We call upon food agencies to reassess Acceptable Daily Intake (ADI) levels for aspartame. We note that an Advisory Group to the International Agency for Research on Cancer has recommended high-priority reevaluation of aspartame’s carcinogenicity to humans.

scholarly journals REVIEW OF THE CURRENT STATE OF THE PROBLEM OF PRIMARY DETECTION OF MALIGNANT TUMORS OF THE CAVITY

2019 ◽  
Vol 15 (2) ◽  
pp. 50-55
Author(s):  
Наталья Нуриева ◽  
Natal'ya Nurieva ◽  
Александр Гузь ◽  
Aleksandr Guz ◽  
Александр Захаров ◽  
...  
Keyword(s):  
Oral Cavity ◽  
Head And Neck ◽  
Malignant Tumors ◽  
Malignant Neoplasm ◽  
Diagnostic Procedures ◽  
Primary Diagnosis ◽  
Malignant Neoplasms ◽  
Dental Rehabilitation ◽  
Late Treatment ◽  
Clinically Significant

Subject: malignant neoplasms of the oral cavity, primary detectability, appeal to specialists, terms of treatment before hospitalization. Objective: based on a five-year analysis of the medical records of patients with a verified diagnosis of malignant neoplasm of the oral cavity, to identify significant criteria for primary diagnosis, doctors of the first contact, including non-cancer profile. Methodology. Malignant neoplasms occupy one of the leading places among all medical and social problems. This is due to a number of reasons, among which are particularly high rates of morbidity and mortality, late treatment of patients and frequent disability. the Purpose of early detection of malignant tumors of the oral cavity is to increase the effectiveness and radicality of treatment, increase the possibility of dental rehabilitation, reduction of disability. To write this article, we conducted a five-year analysis of the primary detection of malignant tumors of the oral cavity in 76 patients hospitalized for treatment in the head and neck Department of the Chelyabinsk district Oncology center. All patients with histologically confirmed diagnosis. Everyone needs specialized anti-tumor treatment. In addition to standard diagnostic procedures, all patients were surveyed on the issues of primary complaints and appeals to medical specialists. Results. On the example of the received questionnaires as well as the standard medical examinations conducted upon admission to the head and neck Department, the trends of the primary referral of patients to primary contact doctors, the terms of treatment before referral to a specialized oncological institution, the stage of the process and the presence of metastasis of the primary focus during treatment, the presence of aggravating factors are analyzed. Conclusions. The results for the five-year period in patients with primary malignant neoplasm of the oral cavity were evaluated, practical recommendations on clinically significant symptoms of malignant tumors of the oral cavity, orientation on the timing of observation were given.

scholarly journals Uncoupled biological and chronological aging of neutrophils in cancer promotes tumor progression

2021 ◽  
Vol 9 (12) ◽  
pp. e003495
Author(s):  
Laura A Mittmann ◽  
Florian Haring ◽  
Johanna B Schaubächer ◽  
Roman Hennel ◽  
Bojan Smiljanov ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Tumor Progression ◽  
Immune Cells ◽  
Malignant Tumors ◽  
Ex Vivo ◽  
Biological Aging ◽  
Malignant Neoplasms ◽  
Chronological Aging ◽  
Functional Changes

BackgroundBeyond their fundamental role in homeostasis and host defense, neutrophilic granulocytes (neutrophils) are increasingly recognized to contribute to the pathogenesis of malignant tumors. Recently, aging of mature neutrophils in the systemic circulation has been identified to be critical for these immune cells to properly unfold their homeostatic and anti-infectious functional properties. The role of neutrophil aging in cancer remains largely obscure.MethodsEmploying advanced in vivo microscopy techniques in different animal models of cancer as well as utilizing pulse-labeling and cell transfer approaches, various ex vivo/in vitro assays, and human data, we sought to define the functional relevance of neutrophil aging in cancer.ResultsHere, we show that signals released during early tumor growth accelerate biological aging of circulating neutrophils, hence uncoupling biological from chronological aging of these immune cells. This facilitates the accumulation of highly reactive neutrophils in malignant lesions and endows them with potent protumorigenic functions, thus promoting tumor progression. Counteracting uncoupled biological aging of circulating neutrophils by blocking the chemokine receptor CXCR2 effectively suppressed tumor growth.ConclusionsOur data uncover a self-sustaining mechanism of malignant neoplasms in fostering protumorigenic phenotypic and functional changes in circulating neutrophils. Interference with this aberrant process might therefore provide a novel, already pharmacologically targetable strategy for cancer immunotherapy.

scholarly journals Тhe effect of cancer patients’ positioning accuracy during radiation therapy sessions using medical linear electron accelerators on the parameters of their individual 3D dose distribution

Doklady BGUIR ◽  
2020 ◽  
Vol 18 (7) ◽  
pp. 31-39
Author(s):  
M. N. Piatkevich ◽  
E. V. Titovich ◽  
G. V. Belkov
Keyword(s):  
Radiation Therapy ◽  
Radiation Treatment ◽  
Malignant Tumors ◽  
Rapid Development ◽  
Treatment Session ◽  
Malignant Neoplasms ◽  
Horizontal Position ◽  
Individual Dose ◽  
Dose Distributions ◽  
The Impact

Due to the rapid development and further improvement of radiation treatment technologies oncologists have an opportunity to precisely deliver individual dose distributions to the tumor, minimizing the doses obtained by critical organs and healthy structures. For the correct and successful application of these complex methods of radiation therapy, it was necessary to enforce the requirements for the technical and dosimetric parameters of the radiotherapy equipment. The purpose of the research is to determine the magnitude of the possible error for patients’ positioning during their radiotherapy treatments using medical linear accelerators by modeling the impact of the patient’s body on the treatment couch. To determine the values of a possible error, the authors have considered the design and characteristics of a typical treatment couch, developed a model of the “average” patient’s body (phantom), which allowed changing the load to the treatment couch with a step of 1 kg. The position parameters of treatment couches were determined for the main types of localization of radiation therapy for malignant tumors: head and neck tumors, breast tumors and pelvic tumors. Numerical values of the treatment coach deviations from prescribed horizontal position were experimentally established for a load from 40 to 180 kg for a treatment couch used at the N.N. Alexandrov National Cancer Centre of Belarus. Based on the obtained experimental data, the necessity to correct the patient's treatment conditions at the stage of treatment planning were confirmed in order to ensure the delivery accuracy of individual dose distributions as required by the radiation therapy protocols. Authors stated that an analysis of the dependence of the deviations in the dose delivered to the patients on the deviation of the radiotherapy table from its horizontal position should be carried out for each radiotherapy table used in clinical practice. The development and implementation of a mechanism that will allow considering this information when choosing the parameters of the patient’s treatment session and prescribing the dose for any localization of malignant neoplasms is needed.

Paraneoplastic movement disorders

2018 ◽  
Vol 29 (7) ◽  
pp. 745-755 ◽  
Author(s):  
Karolina Popławska-Domaszewicz ◽  
Jolanta Florczak-Wyspiańska ◽  
Wojciech Kozubski ◽  
Sławomir Michalak
Keyword(s):  
T Cell ◽  
Cell Surface ◽  
Movement Disorders ◽  
Clinical Symptoms ◽  
Early Recognition ◽  
Neuronal Loss ◽  
Synaptic Proteins ◽  
Malignant Neoplasms ◽  
Cell Surface Antigens ◽  
Opsoclonus Myoclonus Syndrome

Abstract Paraneoplastic movement disorders are rare, autoimmune-mediated, nonmetastatic complications of malignant neoplasms. Common paraneoplastic movement disorders include paraneoplastic chorea, dystonia, cerebellar degeneration, different types of encephalitis, opsoclonus-myoclonus syndrome, stiff person syndrome, and neuromyotonia. Syndromes usually develop before tumor diagnosis, have subacute onset, and are associated with serum or cerebrospinal fluid antibodies. Two types of antibodies can be distinguished: antibodies against nuclear and cytoplasmic neuronal antigens (anti-Hu, anti-Ri, anti-Yo, anti-Ma, anti-CV2/CRMP5, anti-Gephrin, and anti-GABATRAP) and antibodies recently identified against cell surface and synaptic proteins (anti-NMDAR, anti-LGI1, and anti-Caspr2). These two types differ from each other in a few important aspects. Antibodies against cell surface and synaptic protein disrupt cell-surface antigens. Clinical symptoms are related to the disruption of antigens and potentially can be reversed by immunotherapy. The association between these antibodies and malignancy is much less consistent. On the other hand, antibodies against nuclear and cytoplasmic neuronal antigens seem to be not pathogenic; however, they most likely indicate a T-cell-mediated immune response against neurons. Due to T-cell-mediated neuronal loss, response to immunotherapy is generally disappointing. Early recognition of all these diseases is crucial because it may lead to the disclosure of occult cancer. This review is focused on paraneoplastic movement disorders with emphasis on clinical presentations, investigational findings, and therapeutic results.

Malignant Tumors of the Spleen

2017 ◽  
Author(s):  
Alessandro Paniccia ◽  
Brandon Chapman ◽  
Ana Gleisner
Keyword(s):  
Malignant Tumors ◽  
Primary Treatment ◽  
Malignant Neoplasms ◽  
Resonance Imaging ◽  
Lymphoproliferative Diseases ◽  
Metastatic Lesions ◽  
Radiologic Imaging ◽  
Splenic Tumor ◽  
Myeloproliferative Diseases ◽  
Splenic Lymphoma

Malignant tumors of the spleen are rare lesions that can be divided into three broad categories: lymphoproliferative diseases, metastatic lesions, and primary splenic (nonlymphoid) malignant neoplasms. Additionally, although myeloproliferative diseases are not tumors of the spleen, they do have the potential to either directly or indirectly affect splenic function, often manifesting as splenomegaly, hypersplenism, or both. Lymphoproliferative and myeloproliferative diseases are almost always systemic diseases. Consequently, medical therapy is the primary treatment, and splenectomy is currently reserved for patients with hematologic disorders refractory to medical management—for palliation of symptoms caused by splenomegaly or hypersplenism—and in the rare case of the pure splenic form of the disease. Patients affected by malignant splenic lesions often present with vague symptomatology, including generalized malaise, fatigue, weight loss, and fever. These symptoms may be accompanied by abdominal pain, a palpable left upper quadrant mass, or overt splenomegaly. Radiologic imaging, including ultrasonography, computed tomography, and magnetic resonance imaging, is mandatory in the evaluation of splenic tumors and may narrow the differential diagnosis. Management of splenic metastases should be individualized and, whenever possible, determined in a multidisciplinary setting. Splenectomy is the treatment of choice for patients with primary malignant tumors of the spleen in the absence of metastatic disease.  This review contains 10 figures, 8 tables and 51 references Key words: angiosarcoma, leukemia, malignant splenic tumor, metastatic splenic tumor, spleen, splenectomy, splenic lymphoma  

Simultaneous Malignant and Benign Nonepithelial Neoplasms of the Larynx—A Case Report and Literature Review

2020 ◽  
pp. 014556132092556
Author(s):  
Przemyslaw Krawczyk ◽  
Antoni Bruzgielewicz ◽  
Kazimierz Niemczyk
Keyword(s):  
Case Report ◽  
Benign Tumor ◽  
Malignant Tumors ◽  
Treatment Options ◽  
Thyroid Cartilage ◽  
Simultaneous Occurrence ◽  
Malignant Neoplasms ◽  
Tumor Localization ◽  
Striated Muscles ◽  
Histopathological Evaluation

Nonepithelial tumors of the larynx are relatively rare neoplasms of the head and neck. The chondrosarcoma, which develops commonly from cricoid and thyroid cartilage, stands for 0.2% of the laryngeal malignant neoplasms. The rhabdomyoma is even more uncommon benign tumor developing from the laryngeal striated muscles. The clinical manifestation and the treatment options depend on the histopathological evaluation, tumor localization, and its size. In presented case, the simultaneous occurrence of benign and malignant tumors of mesenchymal origin in the patient’s larynx was provoking hoarseness, globus sensation, and dysphagia. To the best of authors’ knowledge, no other case of the concomitance of rhabdomyoma and chondrosarcoma of the larynx have been reported in the literature.

scholarly journals Clinicopathological and Prognostic Significance of CBX3 Expression in Human Cancer: a Systematic Review and Meta-analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Hexin Lin ◽  
Xin Zhao ◽  
Lu Xia ◽  
Jiabian Lian ◽  
Jun You
Keyword(s):  
Malignant Tumors ◽  
Human Cancer ◽  
Meta Analysis ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Cancer Prognosis ◽  
High Expression ◽  
Clinicopathological Parameters ◽  
Malignant Neoplasms ◽  
Tumor Type

Background. Chromebox protein homolog 3 (CBX3) as a member of the heterochromatin-associated protein 1 (HP1) family has been reported to be overexpressed in human cancer tissues. Numerous studies have shown the relationship between the CBX3 expression and clinicopathological factor or prognosis in malignant tumors, but their results are inconsistent. To address these results, a meta-analysis was described to investigate the prognostic value and clinicopathological significance of CBX3 expression in human malignant neoplasms. Methods. PubMed, Web of Science, Embase, and Chinese National Knowledge Infrastructure (CNKI) were used to search eligible literatures, including publications prior to September 2019. The role of CBX3 in cancer prognosis and clinicopathological characteristics was assessed by pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs). Results. Eleven studies with 1682 cancer patients were enrolled in this meta-analysis. This analysis demonstrated that the patients’ increased CBX3 expression was significantly associated with poor overall survival (OS) (univariate analysis: HR = 1.81 , 95% CI 1.46-2.25; multivariate analysis: HR = 1.95 , 95% CI 1.63-2.34). Subgroups analysis by tumor type also indicated that high expression of CBX3 was correlated with poor OS in tongue squamous cell carcinoma ( HR = 3.31 , 95% CI 2.03-5.39), lung cancer ( HR = 1.66 , 95% CI 1.21-2.29), genitourinary cancer ( HR = 2.03 , 95% CI 1.15-3.58), and digestive cancer ( HR = 1.48 , 95% CI 1.23-1.79). For clinicopathological features, high expression of CBX3 was associated with lymph node metastasis ( OR = 2.96 , 95% CI 1.42-6.20) and lager tumor size ( OR = 1.60 , 95% CI 1.12-2.28). Conclusion. The results of this meta-analysis indicated that CBX3 expression may be a novel biomarker for predicting patient prognosis and clinicopathological parameters in multiple human cancer.

Sign in / Sign up

Export Citation Format

Share Document